ESR1 and neoplasm: We present here the development and analytical validation of a highly sensitive and specific NAPA assay for the detection of four ESR1 mutations (Y537S, Y537C, Y537N and D538G) in the primary tumours, CTCs, and plasma-ctDNA of ER+ BrCa patients.